ReviewJournal of the Chinese Medical Association : JCMA2026
Respiratory syncytial virus infection in adults: Clinical manifestations, outcomes, and vaccines.
Review in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is an RNA virus transmitted via droplets and affects individuals across all age groups. Although RSV is increasingly being recognized as a key pathogen in adults, differentiating RSV infection from other acute viral infections solely on the basis of clinical features is challenging. Polymerase chain reaction is the gold standard for RSV detection. Notably, RSV accounts for 2% to 10% of all hospitalizations due to respiratory tract infections in adults. Among hospitalized adults with RSV infection, 18.9% require intensive care, experiencing a disease burden similar to that of influenza. Severe RSV infection disproportionately affects older adults with multiple comorbidities, such as chronic heart failure and chronic obstructive pulmonary disease. This review focused on the manifestations and outcomes of RSV infection and on advances in the development of RSV vaccines. We comprehensively searched PubMed for relevant studies published between 1991 and 2024. Evidence specific to RSV treatments remains limited, with supportive care being the mainstay of management. In 2023, two protein subunit vaccines were approved for individuals aged ≥60 years; in addition, an mRNA-based vaccine that exerts substantial protective effects against severe RSV disease received approval in the United States. The development of novel antiviral therapies and vaccines holds promise for mitigating the burden of RSV infection. However, further research is required to evaluate the real-world effectiveness of vaccines, particularly in high-risk hospitalized patients requiring intensive care or mechanical ventilation, to optimize implementation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.